Pharmaxis today announced that at its recent meeting, the Australian Advisory Committee on Prescription Medicines (ACPM) has recommended approval of Bronchitol (inhaled dry powder mannitol) for marketing in Australia for the treatment of cystic fibrosis.

Read Media Release